病毒特异性T细胞治疗移植后BK多瘤病毒感染
该研究用供者来源或第三方BK多瘤病毒(BKPyV)特异性T细胞(VSTs)治疗38例造血干细胞移植(HSCT)和3例实体器官移植(SOT)受者的BKPyV感染,病毒血症总缓解率86%,出血性膀胱炎100%,安全性良好。
要点
- BKPyV VSTs治疗病毒血症缓解率86%,出血性膀胱炎100%。
- 未发生输注毒性、新发移植物抗宿主病或器官排斥。
- 输注后外周血单核细胞干扰素-γ反应证实BKPyV特异性免疫应答。
核心结论
- BKPyV特异性T细胞是治疗HSCT和SOT受者BKPyV感染及相关症状的安全且可能有效的策略。
主要发现
- 治疗病毒血症患者的总缓解率为86%。
- 治疗出血性膀胱炎患者的总缓解率为100%。
- 同时治疗病毒血症和出血性膀胱炎患者的总缓解率为87%。
- 未发生归因于VST输注的输注毒性、新发移植物抗宿主病或器官排斥。
- 输注后外周血单核细胞对BKPyV抗原产生干扰素-γ,证实BKPyV特异性免疫应答。
关键数值与推荐
- 病毒血症总缓解率86%。
- 出血性膀胱炎总缓解率100%。
- 病毒血症合并出血性膀胱炎总缓解率87%。
临床怎么用
- 对于BKPyV感染且存在免疫抑制、有并发症风险的移植受者,应考虑细胞治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BK polyomavirus (BKPyV) infection is a major complication of hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). Treatment options are limited, poorly effective, and have significant toxicities. Cellular therapy using T cells directed against BKPyV is an emerging therapy, and we report efficacy in controlling BKPyV-associated disease in highly immunocompromised patients. Virus-specific T cells (VSTs) against BKPyV were manufactured using either blood from the patient's stem cell donor (donor-derived VSTs) or from unrelated donors (third-party VSTs). VSTs were used to treat BKPyV in 38 HSCT recipients and 3 SOT recipients between June 2017 and December 2019. Overall response rate was 86% in patients treated for BK viremia, 100% in patients treated for hemorrhagic cystitis, and 87% in patients treated for both BK viremia and hemorrhagic cystitis. No infusional toxicity, de novo graft-versus-host disease, or rejection of the organ occurred attributable to the VST infusion. BKPyV-specific immune responses were demonstrated by interferon-γ production by peripheral blood mononuclear cells postinfusion in response to BKPyV antigens. VSTs are a safe and potentially effective strategy to treat BKPyV and associated symptoms in recipients of HSCT and SOT. Cellular therapy should be considered for all patients with BKPyV and underlying immune suppression at risk of complications. This trial was registered at www.clinicaltrials.gov as #NCT02532452.
引用
- Nelson AS, Heyenbruch D, Rubinstein JD, et al. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Adv. 2020. PMID: 33216887. doi:10.1182/bloodadvances.2020003073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。